Xepenta-L Capsule SR is a sustained-release formulation combining Levosulpiride 75 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders characterized by dyspepsia, gastroesophageal reflux disease (GERD), and functional dysmotility. Levosulpiride, a selective dopamine D2 receptor antagonist, exerts prokinetic and antiemetic effects by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and abdominal discomfort. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The sustained-release mechanism ensures prolonged therapeutic plasma levels, optimizing efficacy and improving patient compliance through once-daily dosing. Xepenta-L Capsule SR is indicated for patients with combined acid-peptic disorders and motility disturbances, providing a synergistic approach to symptom control and mucosal protection. It should be used under medical supervision, with caution advised in patients with hypersensitivity to either component, severe hepatic impairment, or pre-existing neurological conditions. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize potential risks.